Richard, Patrick

Professeur, Faculté de médecine et des sciences de la santé
FMSS Département de chirurgie

Coordonnées

Courriel


--

Diplômes

(2016) Postdoctorat (Fellowship). Princess Margaret Cancer Centre.

(2015) Maîtrise avec mémoire (Master of Science). University of Toronto.

(2013) Postdoctorat (Fellowship). McGill University Health Centre.

(2011) Postdoctorat (Fellowship). Centre Hospitalier Univ. de Sherbrooke.

(2008) Equivalent au doctorat (Medicinae Doctor). Université de Sherbrooke.

(2004) Diplôme (Health Sciences). Université de Moncton.

Titres de compétence

Medical license. Collège des médecins du Québec.

Medical license. Conseil médical du Canada.

Specialist urology certificate. Collège des médecins du Québec.

Specialist urology certificate (FRCSC). Collège Royal des Médecins et Chirurgiens du Canada.

Urologic Oncology Surgeon. Society of Urologic Oncology.

Expérience académique

(2017) Director of Robotic surgery program. CIUSSS de l'Estrie - CHUS.

(2016) Assistant Professor. Université de Sherbrooke.

Présentation

Sujets de recherche

Cancer de l'appareil urinaire, Cancer de la prostate, Diagnostic et détection du cancer, Santé communautaire / santé publique.

Disciplines de recherche

Épidémiologie et biostatistique, Urologie.

Mots-clés

active surveillance, immunology of cancer, uro-oncology.

Intérêts de recherche

Urologic oncology cancers with a focus on prostate, bladder and renal cancers

Recherche clinique

Oui

Langues parlées et écrites

Anglais, Français

Prix et distinctions

  • (2022) Clinician-Investigator Junior 1 Salary Award. Fonds de recherche du Québec - Santé (FRQS). (Prix / Récompense).
  • (2019) Best poster award - American Urological Association Annual meeting. American Urological Association. (Distinction).
  • 2012 Amgen Canada Fellows Alliance Program. Amgen Canada. (Prix / Récompense).
  • 2012 Recipient of the Douglas D. Morehouse award. McGill University Health Centre. (Distinction).
  • 2014 Recipient of the Frank McGill Travel Fellowship award. McGill University Health Centre. (Prix / Récompense).
  • 2015 Urologic Fellow teaching award. Princess Margaret Cancer Centre. (Distinction).
  • Best poster award- American Urological Association Annual meeting. American urological Association Annual Meeting. (Distinction).
  • Clinician Scientist Support Award. Centre Hospitalier Univ. de Sherbrooke. (Prix / Récompense).
  • Winner of the 2012 AUA National Residents Bowl champions (as a member of the Northeastern Section team). American Urological Association. (Prix / Récompense).

Financement

Subvention. (Obtenu). Demandeur principal. Canadian Institutes of Health Research / Instituts de recherche en santé du Canada - Project Grant / Subvention Projet. Instituts de Recherche en Santé du Canada (IRSC). Project Grant / Subvention Projet. 696150 $ (2019-2028).

Bourse de recherche. (Obtenu). Chercheur principal. Diminution du sur-traitement et des conséquences associées au traitement des cancers urologiques. Fonds de recherche du Québec - Santé (FRQS). Clinician-Investigator Junior 1 Salary Award. 136363 $ (2018-2022).

Subvention. (Obtenu). Demandeur principal. Surveillance of Complex Renal Cysts – the SOCRATIC pilot study. Université de Sherbrooke. Concours départemental – Fonds de Recherche – 2019. 25000 $ (2019-2021).

Subvention. (Obtenu). Co-chercheur. Optimiser les soins des patients atteints du cancer de la prostate résistant à la castration en utilisant une stratégie de triple traceur en imagerie moléculaire et en radiothérapie ciblée. Fonds de recherche du Québec - Santé (FRQS). Fondation du CHU de Québec. ONCOPOLE. 1500000 $ (2018-2021).

Subvention. (Obtenu). Co-chercheur. Agir ensemble en faveur de la résilience d'équipes dans le réseau de cancérologie du Québec: Une étude pilote misant sur la capacité de transformation des équipes.. Réseau de recherche en interventions en sciences infirmières du Québec. Concours RRISIQ - Projets Intégrateurs 2019. 90000 $ (2019-2021).

Subvention. (Obtenu). Co-chercheur. Look and Listen. Centre du recherche du CHUS. Axe Inflammation-douleur. 20000 $ (2019-2020).

Subvention. (Obtenu). Chercheur principal. Role of active surveillance in complex renal cysts: a pilot study. Q-CROC. Pilot Study Support Grant. 2000 $ (2019-2020).

Subvention. (Obtenu). Chercheur principal. Starting funds. CHUS Research Center (CRCHUS). Starting funds. 50000 $ (2017-2020).

Subvention. (Terminé). Demandeur principal. Surveillance of Complex Renal Cysts - The SoCRAtiC trial: Focus Group Discussion. Kidney Cancer Canada - Kidney Cancer Research Network of Canada. Kidney Cancer Research Grant. 50000 $ (2018-2019).

Subvention. (Terminé). Demandeur principal. Surveillance of Complex Renal Cysts - The SoCRAtiC trial: Survey of current management. Association Canadienne d'Urologie. CUASF - New Investigator Research Scholarship. 40000 $ (2018-2019).

Subvention. (Terminé). Co-chercheur. Oncolytic Vesicular Stomatitis Virus for the treatment of non-muscle invasive bladder cancer in humanized mice. CHUS Research Center (CRCHUS). Programme Projets Structurants 2017. 50000 $ (2017-2018).

Subvention. (Terminé). Co-chercheur. Salary award. CHUS Research Center (CRCHUS). Salary award. 50000 $ (2017-2018).

Subvention. (Terminé). Chercheur principal. Identifying and overcoming barriers to widespread adoption of renal tumor biopsies (RTBs) in Canada. Kidney Cancer Research Network of Canada. Research grant. 45000 $ (2016-2017).

Publications

Articles de revue

  • Brière R, Versi E, Richard PO, Gratton M*, Tu LM. (2020). Author Reply. Urology, 136, 94. (Article publié).
  • Richard PO, Timilshina N, Komisarenko M, Martin L, Ahmad A, Alibhai SMH, Hamilton RJ, Kulkarni G, Finelli A. (2020). The long-term outcomes of Gleason grade groups 2 and 3 prostate cancer managed by active surveillance: Results from a large population-based cohort. Can Urol Assoc J. (impact factor: 0.87), NA, NA. (Article sous presse).
  • Prendeville S, Richard PO, Finelli A, Jewett MAS, Kachura JR, Sweet JM, van der Kwast TH, Cheung CC, Evans AJ. (2019). Accuracy of Renal Tumour Biopsy for the Diagnosis and Subtyping of Papillary Renal Cell Carcinoma: Analysis of Paired Biopsy and Resection Specimens with Focus on Discordant Cases. J Clin Path (impact factor: 6.25), 72(5), 363-367. (Article publié).
  • Leão R, Lee D, Figueiredo A, Hermanns T, Wild P, Komosa M, Lau I, Mistry M, Nunes NM, Price AJ, Zhang C, Lipman T, Poyet C, Valtcheva N, Oehl K, Coelho H, Sayyid R, Gomes AM, Prado E Castro L, Sweet J, Vinagre J, Apolónio J, Stephens D, Faleiro I, Fadaak K, Richard PO, Kulkarni G, Zlotta AR, Hamilton RJ, Castelo-Branco P, Tabori U. (2019). Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behaviour of bladder cancer. International Journal of Cancer (impact factor: 7.36), 144(7), 1676-1684. (Article publié).
  • Richard PO, Leão R, Jewett M. (2019). Contemporary management of small renal masses. BJUI knowledge, -, -. DOI. (Article publié).
  • Riikonen JK, Guyatt GH, Kilpeläinen T, Craigie S, Arnav Agarwal A, Agoritsas T, Couban R, Dahm P, Järvinen P, Montori V, Power N, Richard PO, Rutanen J, Santti H, Tailly T, Violette PD, Zhou Q, Tikkinen K. (2019). Decision aids for prostate cancer screening choice: a systematic review and meta-analysis. JAMA Inter Med (impact factor: 19.98), NA, NA. (Article sous presse).
  • Choinière R*, Richard PO, Morin M, Tu LM, Violette PD. (2019). Evaluation of benefits and harms of surgicaltreatments for post-radical prostatectomy urinary incontinence: a systematicreview and meta-analysis protocol. F1000 Research, 8, 1155. (Article publié).
  • Choinière R*, Richard PO, Morin M, Tu LM, Violette PD. (2019). Evaluation of benefits and harms of surgical treatmentsfor post-radical prostatectomy urinary incontinence: a systematic review and meta-analysis protocol. F1000 Research, 8, 1155. (Article publié).
  • Asselin C*, Ekindi N, Carignan A, Richard PO. (2019). Gummatous Penile Syphilis. ID Cases, 18, e00589. (Article publié).
  • Lavallée LT, McAlpine K, Kapoor A, Pouliot F, Mason R, Violette PD, Bansal RK, Richard PO, Karakiewicz PI, Bhindi B, Maloni R, Pautler S, Lattouf JB, Kassouf W, Tanguay S, So A, Rendon RA, Breau RH. (2019). KCRNCKidney Cancer Research Network of Canada () consensus statement on the role of renal mass biopsy in the management of kidney cancer. Can Urol Assoc J, 13, 377-383. (Article publié).
  • Mason R, Wood L, Kapoor A, Basappa N, Bjarnason G, Boorjian S, Breau R, Cagiannos I, Jewett M, Karakiewicz P, Kassouf W, Kollmannsberger, Lalani A, Lattouf JB, Lavallée L, Pautler S, Power N, Richard P, So A, Tanguay S, Rendon R. (2019). Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma. Can Urol Assoc J (impact factor 1.18), 13(6), 166-174. (Article publié).
  • Couture F*, Legault B, Ekindi N, Noel-Lamy M, Pavic M, Richard PO. (2019). Malignant solitary fibrous tumour of the kidney with an extensive thrombus: a case report and review of the literature. Urol Case Rep., 26, 100974. (Article publié).
  • Wong ECL, Di Lena R, Breau RH, Pouliot F, Finelli A, Lavallée LT, So A, Tanguay S, Fairey A, Rendon R, Richard PO, Lattouf JB, Kawakami J, Mallick R, Kapoor A. (2019). Morphologic subtyping as a prognostic predictor for survival in papillary renal cell carcinoma: Type 1 vs. type 2. Urol Oncol (impact factor 3.77), 37(10), 712-6. DOI. (Article publié).
  • Richard PO, Finelli A. (2019). Re: Is Routine Renal Tumor Biopsy Associated with Lower Rates of Benign Histology following Nephrectomy for Small Renal Masses?. J Urol (impact factor 5.38), NA, NA. DOI. (Article sous presse).
  • Richard PO, Bashir S, Riverin BD, Alibhai SMH, Kim SJ, Ahmad A, Fleshner NE, Gupta A, Mohammed A, Zlotta AR, Kulkarni GS. (2019). Reply by Authors (Risk of Bone Fractures Following UrinaryIntestinal Diversion: A Population Based Study). J Urol (impact factor 5.38), 202(2), 325. (Article publié).
  • Richard PO, Bashir S, Riverin BD*, Alibhai SMH, Kim S.J, Ahmad A, Fleshner NE, Gupta A, Mohammed A, Zlotta AR, Kulkarni GS. (2019). Risk of Bone FracturesFollowing Urinary Intestinal Diversion: A Population-based Study. J Urol (impact factor 5.38), 202(22), 319-325. (Article publié).
  • Ahmad AE, Mohammed A, Bhindi B, Richard PO, Fadaak K, Leão R, Finelli A, Fleshner NE, Kulkarni GS. (2019). Serum Adipokines as Predictors for the Outcome of Prostate Biopsies at Early Stage Prostate Cancer Diagnosis. Cancer Management and Research (impact factor: 2.24), 11, 10043-10050. (Article publié).
  • Nguyen DD, Lee JY, Couture F, Richard PO, Fahmy N, Perrotte P, Domes T, Bhojani N. (2019). The AFMC electives diversification policy: Potential drawbacks and benefits for medical students applying to urology. Can Urol Assoc J (impact factor 1.18), April, 1. DOI. (Article publié).
  • Richard PO, Martin L, Lavallée LT, Violette PD, Komisarenko M, Evans AJ, Jain K, Jewett MAS, Finelli A. (2018). Can Urol Assoc J (impact factor: 1.18), 12(8), 260-266. (Article publié).
  • Richard PO, Ahmad AE, Bashir S, Zlotta A, Bhindi B, Leao R, Nayan M, Mohammed A, Fleshner NE, Kulkarni GS. (2018). Impact of oral hypoglycemic agents on mortality among diabetic patients with non-muscle invasive bladder cancer: a population-based analysis. Can Urol Assoc J (impact factor: 1.18), 12(6), 203-210. DOI. (Article publié).
  • Richard PO, Lavallée LT, Pouliot F, Komisarenko M, Martin L, Latouff JB, Finelli A. (2018). Is routine use of renal tumor biopsy associated with lower rates of benign histology following nephrectomy for small renal masses?. J Urol (impact factor: 5.38), 200(4), 731-736. DOI. (Article publié).
  • Klotz L, Shayegan B, Guillemette C, Collings LL, Gotto G, Guérette D, Jammal MP, Pickles T, Richard PO, Saad F. (2018). Testosterone Suppression in the Treatment of Recurrent or Metastatic Prostate Cancer – A Canadian Consensus Statement. Can Urol Assoc J (impact factor: 1.18), 12, 30-37. (Article publié).
  • Simard H, Sabbagh R, Ouellet S, Richard P, Jeldres C. (2018). The Impact of Targeted-Therapy on Healthcare Resource Utilisation in patients with Metastatic Renal Cell Carcinoma: The University of Sherbrooke Experience. Can Urol Assoc J (impact factor: 1.18), ND, ND. (Article publié).
  • Richard PO, Violette PD, Jewett MAS, Pouliot F, Leveridge M, So A, Whelan TF, Rendon R, Finelli A. (2017). CUA guideline on the management of cystic renal lesions. Can Urol Assoc J (impact factor: 1.18), 11(3-4), E66-E73. (Article publié).
  • Hu J, Aprikian A, cury FL, Vanhuyse M, Zakaria AS, Richard PO, Perreault S, Dragomir A. (2017). Comparison of surgery and radiation as local treatments in the riskof loco-regional complications in men subsequently dying from prostate cancer. Clin Genitourin Cancer. (Impact factor: 2.54; # 9 urology journal according to SCImago Journal Rank), S1558-7673(17), 30266-5. (Article publié).
  • Richard PO, Ahmad AE*, Bashir S, Hamilton RJ, Nam RK, Leao R*, Jeldres C, Kulkarni G. (2017). Effect of Statins as a Secondary Chemopreventive Agent Among Individuals With Non-Muscle Invasive Bladder Cancer: A Population-Based Analysis. Urol Oncol (impact factor: 3.77), 35(6), 342-348. DOI. (Article publié).
  • Sourial MW*, Richard PO, Bettez M, Jundi M, Tu LM. (2017). Mitomycin-c andurethral dilatation: a safe, effective and minimally invasive procedure forrecurrent vesico-urethral anastomotic stenoses. Urol Oncol (Impact factor: 3.77), 35(12), 672.e15-672.e19. (Article publié).
  • Richard PO, Jewett MA, Finelli A. (2017). Re: Alexander Kutikov, Marc C. Smaldone, Robert G. Uzzo, Miki Haifler, Gennady Bratslavsky, Bradley C. Leibovich. Renal Mass Biopsy: Always, Sometimes, or Never? Eur Urol. 2016;70:403-6. Eur Urol (impact factor: 16.27), 71(2), e45-46. DOI. (Article publié).
  • Sourial MW*, Richard PO, Morisset J, Jundi M, Tu LM. (2017). Retrograde leak point pressure measurement improves outcomes of the Virtue Male Sling for post-prostatectomy incontinence. Can Urol Assoc J (impact factor: 1.18), 11(7), E271-6. (Article publié).
  • Richard PO, Jewett MA, Tanguay S, Saarela O, Liu ZA, Pouliot F, Kapoor A, Rendon R, Finelli A. (2017). Safety, reliability and accuracy of small renal tumour biopsies: results from a multi-institution registry. BJU Int (impact factor: 4.44), 119(4), 543-549. DOI. (Article publié).
  • Leao R*, Ahmad AE*, Richard PO. (2017). Should small renal mass be biopsied?. Curr Urol Rep (impact factor: 2.12), 18(1), 7. (Article publié).
  • Richard PO, Jewett MA, Bhatt JR, Evans AJ, Timilsina N, Finelli A. (2016). Active Surveillance for Renal Neoplasms with Oncocytic Features is Safe. J Urol (impact factor: 5.16), 195(3), 581-587. (Article publié).
  • Komisarenko M, Wong LM, Richard PO, Timilshina N, Toi A, Evans A, Zlotta A, Kulkarni G, Hamilton R, Fleshner N, Finelli A. (2016). An Increase in Gleason 6 Tumor Volume While on Active Surveillance Portends a Greater Risk of Grade Reclassification with Further Followup. J Urol (impact factor: 5.16), 195(2), 307-312. (Article publié).
  • Leao R*, Richard PO, Jewett MAS. (2016). Approach to Managing Small Renal Masses. BJUI knowledge, N/A, N/A. DOI. (Article publié).
  • Richard PO, Jewett MAS. (2016). Editorial comments. Refers to article: Size and volumetric kinetics of renal masses in patients with renalcell carcinoma. Urology (impact factor: 2.31), 90, 124. (Article publié).
  • Nayan M, Richard PO, Jewett MA, Kachura JR, Evans A, Hamilton RJ, Finelli A. (2016). Hematologic Parameters to Predict Small Renal Mass Biopsy Pathology. Clin Genitourin Cancer (impact factor: 2.53), 14(3), 226-230. DOI. (Article publié).
  • Bhindi B, Hermanns T, Wei Y, Yu J, Richard PO, Wettstein MS, Templeton A, Li K, Sridhar SS, Jewett MA, Fleshner NE, Zlotta AR, Kulkarni GS. (2016). Identification of the best complete blood count-based predictors for bladder cancer outcomes in patients undergoing radical cystectomy. Br J Cancer (impact factor: 6.17), 114(2), 207-212. (Article publié).
  • Bhatt JR, Jewett MA, Richard PO, Kawaguchi S, Timilshina N, Evans A, Alibhai S, Finelli A. (2016). Multilocular Cystic Renal Cell Carcinoma: Pathological T Staging Makes No Difference to Favorable Outcomes and Should be Reclassified. J Urol (impact factor: 5.16), 196(5), 1350-1355. DOI. (Article publié).
  • Bhatt JR, Richard PO, Kim NS, Finelli A, Manickavachagam K, Legere L, Evans A, Pei Y, Sykes J, Jhaveri K, Jewett MA. (2016). Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs >4cm Can Be Offered Active Surveillance as an Initial Management Strategy. Eur Urol (impact factor: 16.27), 70(1), 85-90. (Article publié).
  • Richard PO, Finelli A. (2016). Percutaneous biopsy for RCC. BJUI Knowledge, (Article publié).
  • Komisarenko M, Timilshina N, Richard PO, Alibhai SM, Hamilton R, Kulkarni G, Zlotta A, Fleshner N, Finelli A. (2016). Stricter Active Surveillance Criteria for Prostate Cancer do Not Result in Significantly Better Outcomes: A Comparison of Contemporary Protocols. J Urol (impact factor: 5.16), 196(6), 1645-1650. DOI. (Article publié).
  • Leao RRN*, Richard PO, Jewett MAS. (2016). The Role of Biopsy for Small Renal Masses. Int J Surg (impact factor: 2.21), 36, 513-517. DOI. (Article publié).
  • Richard PO, Alibhai SM, Panzarella T, Klotz L, Komisarenko M, Fleshner NE, Urbach D, Finelli A. (2016). The uptake of active surveillance for the management of prostate cancer: A population-based analysis. Can Urol Assoc J (impact factor: 1.18), 10(9-10), 333-338. (Article publié).
  • Richard P, Abramsky H, Bhatt JR, Hermanns T, Hersey KM, Chadwick K, Fleshner NE. (2015). Impact of Energy Drinks on Androgen Deprivation Induced Fatigue: Results of a Pilot Study. J Caffeine Res, 5(1), 50-54. (Article publié).
  • Leao RRN*, Richard PO, Jewett MAS. (2015). Indications for biopsy and the current status of focal therapy for renal tumours. Transl Androl Urol, 4(3), 283-293. (Article publié).
  • Jewett MA, Richard PO, Finelli A. (2015). Management of small renal mass: an opportunity to address a growing problem in early stage kidney cancer. Eur Urol (impact factor: 16.27), 68(3), 416-417. (Article publié).
  • Richard PO, Fleshner NE, Bhatt JR, Hersey KM, Chahin R, Alibhai SM. (2015). Phase II, randomised, double-blind, placebo-controlled trial of methylphenidate for reduction of fatigue levels in patients with prostate cancer receiving LHRH-agonist therapy. BJU Int (impact factor: 4.44), 116(5), 744-752. (Article publié).
  • Richard PO, Jewett MA, Bhatt JR, Kachura JR, Evans AJ, Zlotta AR, Hermanns T, Juvet T, Finelli A. (2015). Renal Tumor Biopsy for Small Renal Masses: A Single-center 13-year Experience. Eur Urol (impact factor: 17.58, 95 citations), 68(6), 1007-1013. (Article publié).
  • Richard PO, Finelli A. (2014). 5-Alpha reductase inhibitors in active surveillance. Curr Opin Urol (impact factor: 1.79), 24(3), 324-328. (Article publié).
  • Hermanns T, Bhindi B, Wei Y, Yu J, Noon AP, Richard PO, Bhatt JR, Almatar A, Jewett MA, Fleshner NE, Zlotta AR, Templeton AJ, Kulkarni GS. (2014). Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Br J Cancer (impact factor: 6.17), 111(3), 444-451. (Article publié).
  • Haddad RL , Richard P , Bladou F. (2013). Canada's first robotic-assisted totally intracorporeal orthotopic ileal neobladder. Can Urol Assoc J (impact factor: 0.87), 7(7-8), E537-42. (Article publié).
  • Ploussard G , Haddad R , Kovac E , Richard P , Anidjar M , Bladou F. (2013). Robot-assisted laparoscopic partial nephrectomy: Early single Canadian institution experience. Can Urol Assoc J (impact factor: 0.87), 7(9-10), 348-54. (Article publié).
  • Richard P , Ordonez NI , Tu le M. (2013). The effect of a 6 Fr catheter in women: Are they obstructive?. Can Urol Assoc J (impact factor: 0.87), 7(5-6), 185-188. (Article publié).
  • Richard P , Ordonez NI , Tu le M. (2013). The effect of a 6 Fr catheter on flow rate in men. Urology annals (impact factor: 0.51), 5(4), 264-8. (Article publié).
  • Richard P , Gagnon LO , Tu le M. (2012). "U-method" TVT-Secur slings: Are they obstructive?. Can Urol Assoc J (impact factor: 0.87), 6(2), E104-7. (Article publié).
  • Richard P , Bettez M , Martel A , Ponsot Y , Sabbagh R. (2012). Laparoscopic management of a large staghorn stone. Can Urol Assoc J (impact factor: 0.87), 6(3), E121-4. (Article publié).
  • Richard P , Carmel M , Hage B , Ramsay S , Tu le M. (2011). A modified approach to patient's selection with improved clinical outcomes in sacral nerve modulation. Can Urol Assoc J (impact factor: 0.87), 5(6), 403-8. (Article publié).

Chapitres de livre

  • Bhatt JR, Richard PO, Jewett MAS. (2017). Natural history and active surveillance. Oya M. Renal cell carcinoma – molecular features and treatment updates (Springer). Japon : Springer, Tokyo. (Article publié).
  • Richard PO, Bhatt JR, Finelli A, Jewett MAS. (2016). Small Renal Masses: Role of renal biopsy. Anthem Press Small Renal Masses: diagnosis and management (Anthem Press). Royaume-Uni : Anthem Press. (Article publié).
  • Richard P, Bladou F. (2013). Techniques, indications et résultats du curage ganglionnaire dans le traitement du cancer de la prostate. Université de McGill Encyclopédie Medico-chirurgicale Canada : Elsevier-masson. (Article publié).

Lignes directrices en matière de soins cliniques

  • Mason R, Wood L, Kapoor A, Basappa N, Bjarnason G, Boorjian S, Breau R, Cagiannos I, Jewett M, Karakiewicz P, Kassouf W, Kollmannsberger, Lalani A, Lattouf JB, Lavallée L, Pautler S, Power N, RichardP. (2019). Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma.
  • Violette PD, Jewett MAS, Pouliot F, Leveridge M, So A, Whelan TF, Rendon R, Finelli A. (2017). Guidelines on the management of cystic renal lesions.
  • Klotz L, Shayegan B, Guillemette C, Collins LL, Gotto G, Guérette D, Jammal MP, Pickles T, Richard PO, Saad F. (2017). Testosterone suppression in the treatment of recurrent or metastatic prostate cancer — A Canadian consensus statement.

Articles de conférence

  • Bernier-Godon F, Niavarani S, Lawson C, Richard P, Tai LH. (2019). Characterizing the immune response to oncolytic vesicular stomatitis virus in bladder cancer. 8e Colloque Annuel d’Immuno-Inflammation. (Article accepté).
  • Riikonen J, Guyatt G, Kilpelainen T, Craigie S, Agarwal A, Agoritsas T, Couban R, Dahm P, Jarvinen P, Montori V, Power N, Richard P, Rutanen J, Santti H, Tailly T, Violette P, Zhou Q, Tikkinen K. (2019). Decision aids for prostate cancer screening choice: A systematic review and meta-analysis. McMaster Department of Health Research Methods, Evidence and Impact Research Day. (Article accepté).
  • Camilla Tajzler, Anil Kapoor, Ranjeeta Mallick, Beau Ahrens, Luke T. Lavallée, Rodney H. Breau, Naveen Basappa, Simon Tanguay, Daniel Heng, Frédéric Pouliot, Darrel E. Drachenberg, Georg Bjarnason, Denis Soulieres, Nicholas E. Power, Patrick O. Richard, Christian Kollmannsberger, Antonio Finelli, Lori A. Wood. (2019). Determining generalizability of the Canadian Kidney Cancer information system (CKCis) to the entire Canadian kidney cancer population. 74th Canadian Urological Association Annual meeting. (Article accepté).
  • Gregory Nason, Jonathan Morris, Jaimin Bhatt, Patrick Richard, Lisa Martin, Michael Jewett, Kartik Jhaveri, Alexandre Zlotta, Robert Hamilton, Antonio Finelli. (2019). Natural history of renal angiomyolipoma (AML) favors surveillance as an initial approach. 2019 American Urological Association Annual meeting. (Article accepté).
  • Jake Morris, Gregory J. Nason, Jaimin Bhatt, Patrick O. Richard, Lisa Martin, Michael A. Jewett, Kartik Jhaveri, Alexandre Zlotta, Robert Hamilton, Antonio Finelli. (2019). Natural history of renal angiomyolipoma favours surveillance as an initial approach. 74th Canadian Urological Association Annual Meeting. (Article publié).
  • Félix Couture, Rodney H. Breau, Adrian Fairey, Tony Finelli, Daniel Y. C. Heng, Luke T. Lavallée, Ricardo A. Rendon, Simon Tanguay, Patrick O. Richard. (2019). Patient, tumor and surgeon factors predicting the use of renal tumor biopsy amongst Canadian urologists. 44e Congrès de l'Association des urologues du Québec 2019. (Article accepté).
  • Charles Asselin, Rodney H. Breau, Ranjeeta Mallick, Anil Kapoor, Antonio Finelli, Ricardo A. Rendon, Simon Tanguay, Frédéric Pouliot, Adrian Fairey, Luke T. Lavallée, Franck Bladou, Jun Kawakami, Alan I. So, Patrick Richard. (2019). Post-nephrectomy upstaging of cT1a renal tumor to pT3a: Is renal tumor biopsy predisposing. 44e Congrès de l'Association des urologues du Québec 2019. (Article accepté).
  • Douglas C. Cheung, Patrick O. Richard, Diana E. Magee, Luke T. Lavallée, Frédéric Pouliot, Maria Komisarenko, Lisa Martin, Jean-Baptiste Lattouf, Shabbir M. Alibhai, Murray Krahn, Antonio Finelli. (2019). Renal biopsy: When will it change management?. 2019 American Urological Association Annual meeting, Chicago, USA. (Article accepté).
  • Raphaëlle Brière, Patrick O. Richard, Matthieu Gratton and Le Mai Tu. (2019). The effect of selective bladder denervation in female refractory overactive bladder with or without detrusor overactivity. 2019 American Urological Association Annual Meeting. (Article accepté).
  • Patrick O. Richard, Narhari Timishina, Maria Komisarenko, Lisa Martin, Ardalan Ahmad, Shabbir Alibhai, Robert Hamilton, Girish Kulkarni, Antonio finelli. (2019). The longterm outcomes of Grade Groups 2 and 3 prostate cancer managed by active surveillance: results from a large population-based cohort ***Awarded Best Poster***. 2019 American Urological Association Annual Meeting. (Article accepté).
  • Beaudry MM*, Sabbagh R, Carmel M, Martel A, Jeldres C, Ekindi N, Richard PO. (2018). A 10-year Comparative Retrospective Study of Open vs Laparoscopic Extraperitoneal Radical Prostatectomy: The Sherbrooke experience. Journée scientifique des départements de chirurgie et d’anesthésiologie. (Article accepté).
  • Riikonen J, Guyatt G, Kilpelainen T, Craigie S, Agarwal A, Agoritsas T, Couban R, Dahm P, Jarvinen P, Montori V, Power N, Richard P, Rutanen J, Santti H, Tailly T, Violette P, Zhou Q, Tikkinen K. (2018). Decision aids for prostate cancer screening choice: A systematic review and meta-analysis. 2018 American Urological Association Annual Meeting. (Article accepté).
  • Riikonen J, Guyatt G, Kilpelainen T, Craigie S, Agarwal A, Agoritsas T, Couban R, Dahm P, Jarvinen P, Montori V, Power N, Richard P, Rutanen J, Santti H, Tailly T, Violette P, Zhou Q, Tikkinen K. (2018). Decision aids for prostate cancer screening choice: A systematic review and meta-analysis. 2018 European Urological Association Annual Meeting. (Article accepté).
  • Richard PO, Martin L, Lavallée LT, Violette PD, Komisarenko M, Evans AJ, Jain K, Jewett MAS, Finelli A. (2018). Identifying the barriers of a more widespread adoption of renal tumor biopsies in the management of small renal masses. American Urological Association Annual meeting. (Article accepté).
  • Richard PO, Ahmad AE, Bashir S, Zlotta A, Bhindi B, Leao R, Nayan M, Mohammed A, Fleshner NE, Kulkarni GS. (2018). Metformin use does not impact disease-specific mortality among diabetic patients with non-muscle invasive bladder cancer: A population-based analysis. Canadian Urological Association Annual meeting. (Article accepté).
  • Sourial M, Richard P, Bettez M, Jundi M, Tu LM. (2018). Mitomycin-C and urethral dilatation: A safe, effective and minimally invasive procedure for recurrent vesico-urethral anastomotic stenoses. 2018 Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Annual Meeting. (Article accepté).
  • A. Ahmed, P. Richard, R. Leao,M. Hajiha, L. Martin, M. Komisarenko, R. Grewal, J. Morris, N. Timilshina, A. Zlotta, R. Hamilton, G. Kulkarni, N. Fleshner, A. Finelli. (2018). Outcomes of Radical Prostatectomy Following Initial Active Surveillance. 70th NSAUA annual meeting. (Article accepté).
  • Douglas C. Cheung, Patrick O. Richard, Diana E. Magee, Luke T. Lavallée, Frédéric Pouliot, Maria Komisarenko, Lisa Martin, Jean-Baptiste Lattouf, Shabbir M. Alibhai, Murray Krahn, Antonio Finelli. (2018). Renal biopsy: When will it change management?. 74th Canadian Urological Association Annual meeting. (Article accepté).
  • Richard PO, Martin L, Lavallée LT, Violette PD, Komisarenko M, Evans AJ, Jain K, Jewett MAS, Finelli A. (2017). Identifying the barriers of a more widespread adoption of renal tumor biopsies in the management of small renal masses. Canadian Urological Association Annual meeting 2017. (Article accepté).
  • Richard PO, Alibhai SM, Urbach D, Timilshina N, Fleshner NE, Klotz L, Finelli A. (2017). The Uptake of Active Surveillance for the Treatment of Prostate Cancer in Ontario: A Population-based Study. Canadian Urological Association Annual meeting. (Article accepté).
  • Richard PO, Fleshner NE, Bhatt JR; Hersey KM, Chahin R, Alibhai SM. (2016). A Phase II, Randomized, Double-blind, Placebo-Controlled Trial of Methylphenidate for Reduction of Fatigue in Prostate Cancer Patients Receiving LHRH-Agonist Therapy. American Urological Association Annual meeting. (Article accepté).
  • Bhatt JR, Kawaguchi S, Richard PO, Alibhai S, Timilshina N, Jewett M, Finelli A. (2016). Cystic renal cell carcinoma portends excellent prognosis Results of a large population-level outcome Study. Annual American Urological Assocation Meeting. (Article accepté).
  • Richard PO, Manickavachagam K, Pei Y, Jhaveri K, Evans AJ, Legere L, Finelli A, Jewett MAS. (2016). Renal angiomyolipomas – a large single-center study on its natural history. Annual American Urological Assocation Meeting. (Article accepté).
  • Richard PO, Jewett MA, Bhatt JR, Evans AJ, Timilsina N, Finelli A. (2015). Can oncocytomas be safely monitored by surveillance ?. 2015 Annual American Urological Assocation Meeting. (Article accepté).
  • Richard PO, Jewett MA, Bhatt JR, Kachura JR, Evans AJ, Zlotta AR, Hermanns T, Juvet T, Finelli A. (2014). A large single center study describing the evolution of renal tumor biopsy(N=519; 2001-2013) (BEST POSTER AWARD). American Urological Association Annual meeting. (Article accepté).
  • Bhatt JR, Richard PO, Kim N, Manickavachagam K, Hermanns T, Jewett M. (2014). Glove affair in the O.R. - History of the first surgical rubber glove !. 2014 Annual American Urological Assocation Meeting. (Article accepté).
  • Komisarenko M, Wong LM, Richard P, Timilshina N, Toi A, Evans A, Zlotta A, Girish Kulkarni G, Hamilton R, Fleshner N, Finelli A. (2014). Patients that demonstrate Gleason 6 volume progression on active surveillance have a substantially greater risk of grade progression on further follow-up. Annual American Urological Assocation Meeting. (Article accepté).
  • Richard P, Carmel M. (2008). Rare Case of Spinal Cord Compression Due to Metastatic Testicular Cancer. St Lawrence Urology Group Meeting. (Article accepté).
  • Richard PO, Fleshner NE, Bhatt JR; Hersey KM, Chahin R, Alibhai SM. A Phase II, Randomized, Double-blind, Placebo-Controlled Trial of Methylphenidate for Reduction of Fatigue in Prostate Cancer Patients Receiving LHRH-Agonist Therapy. Society of Urological Oncology Annual Meeting.
  • Bernier-Godon F, Niavarani S, Lawson C, Richard P, Tai LH. Caractérisation de la réponse immunitaire auvirus de la stomatite vésiculaire oncolytique dans le cancer de la vessie. Journée scientifique de la Faculté de médecine et des sciences de la santé.
  • Bernier-Godon F, Niavarani S, Lawson C, Richard P, Tai LH. Caractérisation de la réponse immunitaire au virus de la stomatite vésiculaire oncolytique dans le cancer de la vessie. 60e réunion annuelle club de recherches cliniques du Québec.
  • Bernier-Godon F, Niavarani S, Lawson C, Richard P, Tai LH. Characterizing the immune response to oncolyticvesicular stomatitis virus in bladder cancer. 5th Annual Montreal Immunology Meeting.
  • Bhatt JR, Kawaguchi S, Richard PO, Alibhai S, Timilshina N, Jewett M, Finelli A. Cystic renal cell carcinoma – favourable prognosis regardless of tumour size or T-stage confirmed in large population-level study at ten years follow up. 2015 Annual European Urological Assocation Meeting.
  • Bhindi B, Hermanns T, Wei Y, Yu J, Richard PO, Wettstein MS, Templeton A, Li K, Sridhar SS, Jewett MA, Fleshner NE, Zlotta AR, Kulkarni GS. Determining the best complete blood count-based biomarker for oncologic outcomes following radical cystectomy for urothelial carcinoma of the bladder. Annual American Urological Assocation Meeting.
  • Choiniere R, Violette P, Morin M, Tu L, Reed C, Philie C, Legault B, Beaudry M, Guyatt G, Richard PO. Evaluation of benefits and harms of surgical treatments for post-radical prostatectomyurinary incontinence: systematic review and meta-analysis. 2020 European Urology Association Annual meeting.
  • Choiniere R, Violette P, Morin M, Tu L, Reed C, Philie C, Legault B, Beaudry M, Guyatt G, Richard PO. Evaluation of benefits and harms of surgical treatments for post-radical prostatectomy urinary incontinence: systematic review and meta-analysis. 75th Annual Meeting of the Canadian Urological Association.
  • Choiniere R, Violette P, Morin M, Tu L, Reed C, Philie C, Legault B, Beaudry M, Guyatt G, Richard PO. Evaluation of benefits and harms of surgical treatments for post-radical prostatectomyurinary incontinence: systematic review and meta-analysis. 49th International Continence Society annual meeting.
  • Richard P, Abramsky H, Bhatt JR, Hermanns T, Hersey KM, Chadwick K, Fleshner NE. Impact of Energy Drinks on Androgen Deprivation Induced Fatigue: Results of a Pilot Study. Canadian Urological Association Annual meeting 2014.
  • Raphaëlle Brière, Patrick O. Richard, Matthieu Gratton, Stefan De Wachter, Le Mai Tu. Impact of detrusor overactivity on the efficacy of selective bladder denervation for the treatment of female refractory overactive bladder. 74th Canadian Urological Association Annual Meeting.
  • Bhatt JR, Tanguay S, Liu Z, Richard PO, Kapoor A, Rendon R, Lacombe L, Black P, Pautler S, Breau R, Moore R, Jewett M, Finelli A. Increased uptake of renal tumour biopsies for small renal masses - Results of a multicentre Canadian experience. American Urological Association Annual meeting.
  • Patrick O. Richard, Luke T. Lavallée, Frederic Pouliot, Maria Komisarenko, Lisa Martin, Jean-Baptiste Latouff, Antonio Finelli. Is routine use of renal tumor biopsy associated with lower rates of benign histology following nephrectomy for small renal masses?. 9th Canadian Kidney Cancer Forum.
  • Patrick O. Richard, Luke T. Lavallée, Frederic Pouliot, Maria Komisarenko, Lisa Martin, Jean-Baptiste Latouff, Antonio Finelli. Is routine use of renal tumor biopsy associated with lower rates of benign histology following nephrectomy for small renal masses?. American Urological Association Annual Meeting.
  • Couture F, Nguyen DD, Bhojani N, Lee JY, Richard PO. Knowledge and Confidence Level of Canadian Urology Residents Toward Biostatistics: A National Survey. 75th Annual Meeting of the Canadian Urological Association.
  • Richard P, Ponsot Y, Sabbagh RS. Laparoscopic management of a large stone burden associated with UPJ obstruction. St Lawrence Urology Group Meeting.
  • Timilshina N., Finelli A., Richard PO, Komisarenko M, Martin .L, Tomlinson G, Sander B, Alibhai S. Long-term oncological outcomes following active surveillance of low risk prostate cancer: A population-based study. 2020 European Uological Association Annual meeting.
  • Patrick Richard, Amélie Tétu, Luke T. Lavallée, Philippe Violette, Anil Kapoor, Wassim Kassouf, Antonio Finelli. Management of complex cysts in Canada : Results of a survey study. 74th Canadian Urological Association Annual Meeting.
  • Bettez M, Richard P, Abatzoglou A, Ramsay S, Sabbagh RS. Metastatic renal cancer in the targeted therapy era : The Sherbrooke Experience. St Lawrence Urology Group Meeting.
  • Jundi M, Bettez M, Richard P, Abatzoglou A, Mija F, Ramsay S, Girard N, Carmel M, Asselah J, Sabbagh R. Metastatic renal cancer in the targeted therapy era: The Sherbrooke experience. Canadian Urological Association Meeting.
  • Bhatt JR, Tanguay S, Liu Z, Richard PO, Kapoor A, Rendon R, Lacombe L, Black P, Pautler S, Breau R, Moore R, Jewett M, Finelli A. Multicentre experience of uptake of renal tumour biopsies for small renal masses. European Urological Association annual meeting.
  • Bhatt JR, Kawaguchi S, Richard PO, Alibhai S, Timilshina N, Jewett M, Finelli A. Multilocular cystic renal cell carcinoma has an excellent prognosis regardless of size or pathologic T-stage: Results of a large population-level study. British Urological Association Annual meeting 2015.
  • Bhatt JR, Tse D, Bhindi B, Hermanns T, Richard PO, Kachura J, Hamilton R, Fleshner N, Finelli A, Jewett M, Zlotta A. Novel use of preoperative staging CT scan as a tool to measure visceral adipose tissue (VAT) as a surrogate for body mass index (BMI) to correlate outcomes for patients undergoing radical cystectomy for urothelial cancer of the bladder. American Urological Association Annual meeting.
  • Charles Asselin, Rodney H. Breau,Ranjeeta Mallick, Anil Kapoor, Antonio Finelli, Ricardo A. Rendon, Simon Tanguay, Frédéric Pouliot, Adrian Fairey, Luke T. Lavallée, Franck Bladou, Jun Kawakami, Alan I. So, Patrick O. Richard. Post-nephrectomy upstaging of cT1a to pT3a renal tumour: Is renal tumour biopsy a predisposing factor?. 74th Canadian Urological Association Annual Meeting.
  • Kim M, Bhatt J, Klaassen Z, Bhindi B, Hermanns T, Richard PO, Kachura J, Hamilton RJ, Fleshner N, Finelli A, Jewett M, Zlotta A, Kulkarni G. Predicting Perioperative Complications in Patients Receiving Radical Cystectomy Using Pre-operative CT-Measured Adipose Tissue Indices. American Urological Association Annual meeting.
  • Ploussard G, Haddad R, Kovac E, Richard P, Anidjar M, Bladou F. Pushing the boundaries of robotic assisted partial nephrectomy-Oncological and functional outcomes of localized stage pT1a to pT3a renal tumors. Urological Society of Australia and New Zeland.
  • Richard PO, Bhatt JR, Jewett MAS, Kulkarni GS, Hamilton RJ, Komisarenko M, Zlotta A, Kachura JR, Evans A, Finelli A. Renal Tumor Biopsy for Small Renal Masses: A Single-Center 13-year Experience. European Urological Association Annual meeting.
  • Richard PO, Bashir S, Gupta A, Fleshner NE, Zlotta AR, Mohammed A, Kulkarni G. Risk of Bone Fractures Following Urinary Intestinal Diversion: A Population-based Study. 2018 European Urological Association Annual Meeting.
  • Richard PO, Bashir S, Gupta A, Fleshner NE, Zlotta AR, Mohammed A, Kulkarni G. Risk of Bone Fractures Following Urinary Intestinal Diversion: A Population-based Study. 2018 American Urological Association Annual Meeting.
  • Richard P, Icaza Ordonez N, Tu LM. The Effect of a 6Fr Catheter on Pressure-Flow Studies in Women: Are They Really Obstructive?. Canadian Urological Association Meeting.
  • Richard P, Icaza Ordonez N, Tu LM. The Effect of a 6Fr Catheter on Pressure-Flow Studies in Women : Are They Really Obstructive?. American Urological Association Meeting.
  • Richard P, Icaza Ordonez N, Tu LM. The Effect of a 6Fr Catheter on Pressure-Flow Studies in Women : Are They Really Obstructive?. European Association of Urology Annual Meeting.
  • Richard P, Icaza Ordonez N, Tu LM. The Effect of a 6Fr Catheter on Uroflowmetry in Men. Canadian Urological Association Meeting.
  • Richard P, Gagnon LO, Tu LM. The Voiding Pattern after 'U-Method' TVT-Secur: Is it Obstructive?. Quebec Urological Association Meeting.
  • Couture F, Breau RH, Fairey A, Finelli T, Heng D, Lavallée LT, Rendon RA, Tanguay S, Richard PO. The increasing use of renal tumor biopsy amongst Canadian urologists: When physician perceptions matter most. 75th Annual Meeting of the Canadian Urological Association.
  • Richard PO, Jewett MA, Bhatt JR, Evans AJ, Timilsina N, Finelli A. The natural evolution of oncocytomas: Can they be safely followed by surveillance?. Canadian Urological Association Annual meeting.
  • Richard PO, Jewett MA, Bhatt JR, Evans AJ, Timilsina N, Finelli A. The natural evolution of oncocytomas: Can they be safely followed by surveillance?. Annual European Urological Assocation Meeting.
  • Richard PO, Alibhai SM, Urbach D, Timilshina N, Fleshner NE, Klotz L, Finelli A. The uptake of active surveillance in prostate cancer: results of a population based-study. American Urological Association Annual meeting.
  • Richard P, Ramsay S, Tu LM. Unilateral versus Bilateral Permanent Tined Lead Stimulation in Sacral Nerve Stimulation: Preliminary Results of a Prospective Study. Canadian Urological Association Meeting.
  • Richard P, Ramsay S, Tu LM. Unilateral versus Bilateral Permanent Tined Lead Stimulation in Sacral Nerve Stimulation: Results of a Prospective Study. St Lawrence Urology Group Meeting.
  • Richard P, Ramsay S, Tu LM. Unilateral versus Bilateral Permanent Tined Lead Stimulation in Sacral Nerve Stimulation: Results of a Prospective Study. International Urogynecology Association Meeting.
  • Richard P, Ramsay S, Tu LM. Unilateral versus Bilateral Permanent Tined Lead Stimulation in Sacral Nerve Stimulation: Results of a Prospective Study. International Continence Society Meeting.
  • Bhatt JR, Tse D, Bhindi B, Hermanns T, Richard PO, Kachura J, Hamilton R, Fleshner N, Finelli A, Jewett M, Zlotta A. Visceral Adipose Tissue on Preoperative CT Scan for Urothelial Bladder Cancer and Correlating Outcomes After Radical Cystectomy. British Urological Association Annual meeting 2015.
  • Richard P, Gagnon LO, Tu LM. Voiding Pattern after 'U-Method' TVT-Secur. St Lawrence Urology Group Meeting.
  • Richard P, Gagnon LO, Tu LM. VoidingPattern after 'U-Method' TVT-Secur: Is it Obstructive?. Society of International Urology World Meeting.
  • Richard P, Gagnon LO, Tu LM. VoidingPattern after 'U-Method' TVT-Secur: Is it Obstructive?. International Continence Society and International Urogynecology Association Joint Meeting.
  • Richard P, Gagnon LO, Tu LM. Voiding Pattern after 'U-Method' TVT-Secur: Is it Obstructive?. Canadian Urological Association Meeting.
  • Richard P, Gagnon LO, Tu LM. ‘U-Method’ TVT-Secure: Are They Obstructive?. Department of Surgery Scientific Day – U de Sherbrooke.

Autres contributions

Gestion d'évènements

  • Scientific Committee. (2020). 88th annual meeting of the French Canadian Association for the Advancement of Science /88e Congrès de l'Association Canadienne-Francaise pour l'Avancement de la Science. (Conférence).
  • Organizing Committee. Oncology Scientific Day. (Conférence).

Activités de collaboration internationale

  • Collaborator. (2018). Canada.
  • Collaborator. (2017). Canada. Canadian Kidney Cancer Information System – PI: Rodney Breau (U of Ottawa).
  • Co-investigator. (2018). Canada. Oncopole 3TMPO Study, PI: BGuérin (UofSherbrooke), F Pouliot (ULaval) and JM Beauregard (ULaval).
  • Collaborator. (2017). Canada. · LIPROCA LPC-004 – PI: Richard Casey.
  • Collaborator. (2016). Canada. Étude APPEAL – PI: Philippe Violette (McMasterU) and Kari Tikkinen (Helsinki U)· - MAST – PI: Neil Fleshner (U of Toronto) · -CB-839 WithEverolimus vs. Placebo With Everolimus in Patients With RCC -PI: Sam Withing (Calithera Biosciences).
  • Collaborator. (2016). Canada. Étude MAST – PI: Neil Fleshner (U of Toronto).

Présentations

  • (2020). Imaging in Prostate Cancer: Past, Présent, Future / Imagerie en cancer de la prostate: de hier à aujourd'hui. Urologic Monthly retreat - CISSS de la Montérégie-Centre. Longueuil, Canada.
  • (2020). Reduction of overtreatment in complex renal cysts. 2020 AUA Research Forum: “Early-Career Investigators Showcase”. Washington, États-Unis.
  • Fred Saad, Frédéric Pouliot, Patrick Richard. (2019). L'évolution de la prise en charge du cancer de la prostate avancé: Considérations pour l'urologue (Evolution of advanced prostate cancer: Considerations for urologists). 44e Congrès de l'Association des urologues du Québec 2019. Montreal, Canada.
  • (2019). Le rôle de la biopsie pour la prise en charge des petites masses rénales au Canada / Role of renal tumor biopsy in the management of small renal masses in Canada. 39th annual meeting of the Société Internationale d'Urologie. Athens, Grèce.
  • (2019). Management of Complex Cysts. 39th annual meeting of the Société Internationale d'Urologie. Athens, Grèce.
  • (2019). Management of Complex Cysts: Socratic preliminary studies. 10th Canadian Kidney Cancer Forum. Toronto, Canada.
  • (2019). Means to decrease overtreatment of urological cancers. Atlantic Cancer Research Institute. Moncton, Canada.
  • (2019). What is new in GU oncology?. Best of the American Society of Clinical Oncology. Canada, Canada.
  • (2018). Active Surveillance in the Management of Prostate Cancer: The importance of the pathologist. Colloque Pathologie de la Faculté de Médecine et des Sciences de de la Santé. Orford, Canada.
  • (2018). Follow-up of Non-Muscle Invasive Bladder Cancer. 43rd Annual meeting of the Québec Urological Association. Quebec, Canada.
  • (2018). Management of intermediate-Risk Non-Muscle Invasive Bladder Cancer. 43rd Annual meeting of the Québec Urological Association. Quebec, Canada.
  • (2018). Management of localized and metastatic kidney cancer in 2019. Department of Internal Medicine, Division of Nephrology, CIUSSS de l'Estrie-CHUS. Sherbrooke, Canada.
  • (2018). Management of small renal masses. 18th Annual Canadian Senior Resident Urologic Oncology Course. Montreal, Canada.
  • Richard PO, Kapoor A, Finelli A. (2018). Surveillance of Complex Renal Cysts - The SoCRAtiC Study Proposal. 9th Canadian Kidney Cancer Forum. Toronto, Canada.
  • (2018). Update of the management and follow-up of testicular cancer. Quebec Urological Association semi-Annual meeting. Orford, Canada.
  • (2017). Expert panel on research in medicine. Journée scientifique de chirurgie et anesthésie du CIUSSS de l’Estrie – CHUS. Sherbrooke, Canada.
  • (2017). Ma formation et mon programme de recherche en uro-oncologie. Journée Scientifique Cancer-Inflammation-Douleur. Centre de recherche du CHUS - Université de Sherbrooke. Sherbrooke, Canada.
  • (2017). Role of renal tumor biopsy in kidney cancer. Quebec Urological Association annual meeting. Montreal, Canada.
  • (2017). Treatment of complex renal cystic: one size fits all leads to overtreatment. Canadian Urological Association Annual meeting 2017. Toronto, Canada.
  • (2016). Role of renal tumor biopsies in kidney cancer. Division of urology, CIUSSS de l’Estrie – CHUS. Sherbrooke, Canada.

Les informations disponibles dans la base de données Expertus sont tirées du CV commun canadien.